Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Respiratory Medicine

• Publication date

  2014-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17476348.2014.852960PMID 24308654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ‘The Australian Immunisation Handbook 8th Edition’. National Health and Medical Research Council, Australian Government. Canberra: Commonwealth of Australia; 2003. 350 pages, ISBN 0-642-82204-2

  2015cited by this paper
• Pneumococcal vaccines for cystic fibrosis.

  2014cited by this paper
• Vaccines for preventing influenza in people with cystic fibrosis.

  2014cited by this paper
• [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination].

  2014cited by this paper
• Risk Factors for Respiratory Syncytial Virus Illness Among Patients with Chronic Obstructive Pulmonary Disease

  2013cited by this paper
• Will there ever be a universal Staphylococcus aureus vaccine?

  2013cited by this paper
• Comprehensive Antigen Screening Identifies Moraxella catarrhalis Proteins That Induce Protection in a Mouse Pulmonary Clearance Model

  2013cited by this paper
• Influenza: marketing vaccine by marketing disease

  2013cited by this paper
• Respiratory syncytial virus and asthma: speed-dating or long-term relationship?

  2013cited by this paper
• Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.

  2013cited by this paper
• Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types

  2013cited by this paper
• Respiratory syncytial virus vaccine development.

  2013cited by this paper
• 1 – A short history of vaccination

  2013cited by this paper
• Perplexities of pertussis: recent global epidemiological trends and their potential causes

  2013cited by this paper
• U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

  2013cited by this paper
• Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

  2013cited by this paper
• The role of the bacterial microbiome in lung disease

  2013cited by this paper
• COPD exacerbations: causes, prevention, and treatment.

  2013cited by this paper
• Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: results from a randomized, blinded, controlled trial.

  2013cited by this paper
• Waning Immunity to Pertussis Following 5 Doses of DTaP

  2013cited by this paper
• Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.

  2013cited by this paper
• Vaccines for preventing influenza in people with asthma.

  2013cited by this paper
• Human Rhinoviruses

  2013cited by this paper
• Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis..

  2013cited by this paper
• Pertussis resurgence: waning immunity and pathogen adaptation – two sides of the same coin

  2013cited by this paper
• New aspects on human rhinovirus infections.

  2013cited by this paper
• An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

  2013cited by this paper
• Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial

  2013cited by this paper
• Influenza vaccination in children with cystic fibrosis

  2013cited by this paper
• Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery

  2013cited by this paper
• Strategies to control pertussis in infants

  2013cited by this paper
• Respiratory complications in children hospitalized with varicella.

  2013cited by this paper
• Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults

  2012cited by this paper
• Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media.

  2012cited by this paper
• Long-Term Effects of Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis

  2012cited by this paper
• Pseudomonas infection in chronic obstructive pulmonary disease.

  2012cited by this paper
• Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D–Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial

  2012cited by this paper
• Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999–2010

  2012cited by this paper
• Viral Load and Acute Otitis Media Development After Human Metapneumovirus Upper Respiratory Tract Infection

  2012cited by this paper
• Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

  2012cited by this paper
• Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model

  2012cited by this paper
• Number and order of whole cell pertussis vaccines in infancy and disease protection.

  2012cited by this paper
• Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities.

  2012cited by this paper
• The burden of nonencapsulated Haemophilus influenzae in children and potential for prevention

  2012cited by this paper
• Influenza vaccination coverage among high-risk groups in 11 European countries.

  2012cited by this paper
• Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

  2012cited by this paper
• Principles underlying rational design of live attenuated influenza vaccines

  2012cited by this paper
• Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

  2012cited by this paper
• Epidemiology of influenza A (H1N1)pdm09‐associated deaths in the United States, September–October 2009

  2012cited by this paper
• Challenges for a universal Staphylococcus aureus vaccine.

  2012cited by this paper
• Viruses Associated With Pneumonia in Adults

  2012cited by this paper
• Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media

  2012cited by this paper
• Lower airway microbiology and cellularity in children with newly diagnosed non‐CF bronchiectasis

  2012cited by this paper
• Influenza vaccination coverage and uptake predictors among Spanish adults suffering COPD

  2012cited by this paper
• Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

  2012cited by this paper
• The Worldwide Impact of the Seven-valent Pneumococcal Conjugate Vaccine

  2012cited by this paper
• Barriers to adherence to COPD guidelines among primary care providers.

  2012cited by this paper
• Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.

  2012cited by this paper
• The burgeoning burden of respiratory syncytial virus among children.

  2012cited by this paper
• Is there a future for a Staphylococcus aureus vaccine?

  2012cited by this paper
• Pneumococcal vaccines for cystic fibrosis.

  2012cited by this paper
• Lung function decline from adolescence to young adulthood in cystic fibrosis

  2012cited by this paper
• Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults.

  2012cited by this paper
• Increased risk of pertussis in patients with asthma.

  2012cited by this paper
• Pulsed-Field Gel Electrophoresis Analysis of Bordetella pertussis Isolates Circulating in Europe from 1998 to 2009

  2012cited by this paper
• Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

  2012cited by this paper
• Vaccine development for patients with cystic fibrosis

  2012cited by this paper
• Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

  2011cited by this paper
• Seasonal influenza: the burden of disease in children.

  2011cited by this paper
• Airway microbiology and host defences in paediatric non-CF bronchiectasis.

  2011cited by this paper
• Do New Zealand children with non‐cystic fibrosis bronchiectasis show disease progression?

  2011cited by this paper
• Respiratory syncytial virus vaccine development

  2011cited by this paper
• Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.

  2011cited by this paper
• Bordetella species in children with cystic fibrosis: what do we know? The role in acute exacerbations and chronic course.

  2011cited by this paper
• Haemophilus influenzae Infections in the H. influenzae Type b Conjugate Vaccine Era

  2011cited by this paper
• Rhinovirus vaccination: the case in favour

  2011cited by this paper
• Influenza in young children: burden, immunisation, and policy.

  2011cited by this paper
• Clinical management of Staphylococcus aureus bacteraemia.

  2011cited by this paper
• Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

  2011cited by this paper
• Rhinovirus vaccination: the case against

  2011cited by this paper
• Proposals for the classification of human rhinovirus species C into genotypically assigned types.

  2010cited by this paper
• Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease.

  2010cited by this paper
• A decade of non-cystic fibrosis bronchiectasis 1996-2006.

  2010cited by this paper
• Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab versus nasopharyngeal aspirate using real-time polymerase chain reaction

  2010cited by this paper
• Childhood asthma and infection: virus-induced exacerbations as determinants and modifiers

  2010cited by this paper
• Influenza infection and vaccination in pregnant women

  2010cited by this paper
• Prevalence of viral infection detected by PCR and RT‐PCR in patients with acute exacerbation of COPD: A systematic review

  2010cited by this paper
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  2010cited by this paper
• Vaccines for preventing influenza in the elderly.

  2010cited by this paper
• Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease.

  2010cited by this paper
• Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation

  2010cited by this paper
• Seasonal influenza vaccinations: specialized products for different target groups.

  2010cited by this paper
• Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis.

  2010cited by this paper
• Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.

  2010cited by this paper
• Characterization and Evaluation of the Moraxella catarrhalis Oligopeptide Permease A as a Mucosal Vaccine Antigen

  2010cited by this paper
• Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.

  2010cited by this paper
• Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD.

  2010cited by this paper
• Current progress with Moraxella catarrhalis antigens as vaccine candidates

  2009cited by this paper
• Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations.

  2009cited by this paper
• Moraxella catarrhalis, a human respiratory tract pathogen.

  2009cited by this paper

• Bronchiectasis in Childhood (Including PBB)

  2021cites this paper
• A review of non‐cystic fibrosis bronchiectasis in children with a focus on the role of long‐term treatment with macrolides

  2019cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2019cites this paper
• Health information technology use and influenza vaccine uptake among US adults

  2019cites this paper
• Contemporary management of bronchiectasis in children

  2019cites this paper
• Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.

  2018cites this paper
• The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

  2017cites this paper
• An update on pediatric bronchiectasis

  2017cites this paper
• Pediatric bronchiectasis: No longer an orphan disease

  2016cites this paper
• The genetic diversity of the CbpA gene in Streptococcus pneumoniae

  2015cites this paper
• Antimicrobial treatment of non-cystic fibrosis bronchiectasis

  2014cites this paper